Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83

M Santucci1, N Pimpinelli, L Arganini

  • 1Istituto di Anatomia e Istologia Patologica, Università degli Studi di Firenze, Italia.

Cancer
|May 1, 1991
PubMed

Insights

Primary cutaneous B-cell lymphoma (CBCL) primarily affects the elderly and often remains localized. Despite morphologic variations, CBCL exhibits a low-grade malignancy with a favorable long-term prognosis.

Area of Science:

  • Dermatology
  • Hematology
  • Oncology

Background:

  • Primary cutaneous B-cell lymphoma (CBCL) is a distinct entity requiring precise characterization.
  • Understanding its clinical and morphoimmunologic features is crucial for accurate diagnosis and management.

Purpose of the Study:

  • To investigate the clinical presentation, course, and morphoimmunologic characteristics of primary cutaneous B-cell lymphoma (CBCL).
  • To establish the nature of CBCL and its prognostic implications.

Main Methods:

  • Retrospective analysis of 83 patients with primary cutaneous B-cell lymphoma (CBCL).
  • Evaluation of clinical data, disease presentation, and morphoimmunologic features, including antigenic phenotype of tumor cells.

Main Results:

  • CBCL predominantly affects elderly males (median age 58 years) with frequent locoregional extension (86.7%).
  • Neoplastic cells display features suggesting a mantle-zone origin, with a specific antigenic phenotype (CD19+, CD20+, CD22+, CD28+, CD10-, CD5-, MB2+, CD74+/-, CDw75+/-, MT2+/-, surface immunoglobulin + monoclonal/-).
  • CBCL demonstrates nonaggressive clinical behavior, good response to treatment, and a benign long-term prognosis despite increasing atypism with age.

Conclusions:

  • Primary cutaneous B-cell lymphoma (CBCL) is a unique, low-grade malignancy with a favorable prognosis.
  • Accurate recognition of CBCL is essential to prevent inappropriate treatment strategies.